



## Apic Bio and uniQure Enter into Global Licensing Agreement for APB-102

### Torreya advised Apic Bio on the transaction

Cambridge, MA and Amsterdam and Lexington, MA, January 31, 2023

Apic Bio, an innovative gene therapy company developing novel treatment options for patients with rare genetic diseases, and uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, have entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), a rare, genetic form of ALS. Under the agreement, uniQure acquires global rights for the development and commercialization of APB-102, adding to its pipeline of gene therapies to treat neurological disorders. The U.S. Food and Drug Administration has cleared the investigational new drug (IND) application for APB-102 and has granted Orphan Drug and Fast Track designations.

APB-102 is designed to be a novel, one-time, intrathecally administered gene therapy for ALS caused by mutations in SOD1, a rapidly progressing, rare motor neuron disease that leads to loss of everyday functions and is uniformly fatal. Mutations in the SOD1 gene of ALS account for approximately one-fifth of all inherited forms of this fatal disease<sup>1</sup>. APB-102 is comprised of a recombinant AAVrh10 vector that expresses a micro ribonucleic acid (miRNA) designed to knock down the expression of SOD1 with the goal of slowing down or potentially reversing the progression of ALS in patients with SOD1 mutations.

Under the terms of the agreement, uniQure will make an initial cash payment of \$10 million. In addition, uniQure will pay Apic Bio up to \$45 million in milestones upon achievement of regulatory approvals in the U.S. and Europe and pre-specified annual net sales, and a tiered royalty on net sales ranging from the mid-single digits to low double digits.

Torreya acted as exclusive financial advisor to Apic Bio on the transaction.

#### ABOUT APIC BIO:

For more information about Apic Bio, please see: [www.apic-bio.com](http://www.apic-bio.com)

#### ABOUT UNIQUIRE N.V.:

For more information about uniQure, please see: [www.uniquire.com](http://www.uniquire.com)

#### Deal Press Release

##### Torreya Contacts

###### TIM OPLER

Partner | New York Office

[tim.opler@torreya.com](mailto:tim.opler@torreya.com) | +1 212.257.5802 | [BIO](#)

###### KYLOR HUA

Executive Director | New York Office

[kylor.hua@torreya.com](mailto:kylor.hua@torreya.com) | +1 212.257.5812 | [BIO](#)

Torreya is a global advisory firm serving the life sciences industry. Please visit [torreya.com](http://torreya.com) for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 15 Stratford Place, London W1C 1BE. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.

